Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in disease activity, thus there is a need for novel medications.
Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha. This strategy not only reduced fibrosis but also reversed liver damage.
Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha (FAP). This strategy not only reduced fibrosis but also reversed liver damage.
Rezubio Pharmaceuticals Co. Ltd. has reported new drug conjugates comprising lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of fibrosis.
Mediar Therapeutics Inc. has announced an oversubscribed $76 million series B financing to support its novel anti-fibrotics through clinical studies. The funding will also be used to advance MTX-439 into phase I for the treatment of chronic kidney disease (CKD)-associated fibrosis.
Animate Biosciences Inc. has released new preclinical results demonstrating that AI-designed peptides generated by its Animateiq discovery platform significantly reduced hallmark inflammation and fibrosis signals across multiple human cell types, including skin, lung, heart and liver.
Abbvie Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis and inflammatory disorders.
Researchers at Calluna Pharma AS, Agiana Pharmaceuticals AS and Roskilde University have developed the first humanized IgG4 antibody that inhibits S100A4, which is a calcium-binding protein that helps drive fibrotic inflammatory diseases.
Xortx Therapeutics Inc. has entered into a binding term sheet to acquire a renal anti-fibrotic therapeutic program from Vectus Biosystems Ltd., including a novel new chemical entity, VB4-P5.
In one of the biggest deals of the waning year, Novo Nordisk A/S is buying Akero Therapeutics Inc. to bolster its metabolic dysfunction-associated steatohepatitis (MASH)-treatment portfolio. In the $5.2 billion deal, Akero brings its fibroblast growth factor 21 analogue, efruxifermin, which is in a phase III study for treating those with moderate to advanced liver fibrosis and those with cirrhosis.
